Structural hybridization as a tool for developing novel biologically active analogues of protulactone A

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Cancer Biology

Background:

• Protulactone A is a natural product with potential biological activities.
• Developing novel anticancer agents with improved efficacy and selectivity is a critical need.
• Understanding structure-activity relationships is key to designing effective therapeutics.

Purpose of the Study:

• To synthesize novel hybrid analogues of protulactone A.
• To evaluate the antiproliferative activity of these analogues against a panel of human cancer cell lines.
• To investigate their potential as modulators of multidrug resistance and inducers of apoptosis.

Main Methods:

• Synthesis of twelve novel hybrid analogues using Grignard addition, deprotection, and cyclocondensation reactions.
• Antiproliferative assays against ten tumor cell lines and one normal cell line (MRC-5).
• Analysis of multidrug resistance modulation, apoptosis induction (Caspase-3 activation), and cellular uptake (LC-MS/MS).

Main Results:

• Several analogues (9, 13, 16) exhibited IC50 values below 10 μM against leukemia, breast, and cervical cancer cells.
• Compounds 3, 8, and 11 reduced MRP1 levels and induced apoptosis in K562 cells.
• Structure-activity relationship analysis indicated that a C-7 phenyl group and specific stereochemistry enhance potency.
• Compound 11 demonstrated high uptake and selectivity, being non-toxic to normal cells.

Conclusions:

• Structural hybridization of protulactone A and styryl lactone is a viable strategy for developing novel anticancer agents.
• The synthesized analogues show significant antiproliferative activity and selectivity for tumor cells.
• These compounds hold promise for overcoming multidrug resistance and warrant further investigation as anticancer therapeutics.